Multiple Myeloma
Darzalex Combined with Pomalidomide and Dexamethasone Approved for Relapsed/Refractory Multiple Myeloma
Daratumumab (Darzalex), in combination with pomalidomide (Pomalyst) and dexamethasone, for the treatment of patients with multiple myeloma who have received at least 2 previous therapies, including lenalidomide (Revlimid) and a [ Read More ]
Treatment of Relapsed/Refractory Multiple Myeloma
Despite major and continuing treatment interventions, myeloma remains incurable for most patients, and relapse is an expected part of the disease course. At the National Comprehensive Cancer Network 12th Annual [ Read More ]
Treating Newly Diagnosed Multiple Myeloma in Transplant-Eligible Patients
Recent advances in the treatment of multiple myeloma have dramatically altered the trajectory of disease, as providers now have several efficacious agents in various drug classes at their disposal. At [ Read More ]
This Year, March’s Myeloma Awareness Month Is Myeloma Action Month
Although multiple myeloma is the second most common blood cancer, the majority of patients are unfamiliar with this type of cancer until they are diagnosed with the disease.1 In 2009, [ Read More ]
Perception Is Patients’ Reality: How to Increase Oral Oncolytic Adherence
From 2004 to 2013, 22 new oral anticancer medications were introduced in the United States, which is almost the same number (27) of oral anticancer medications that were introduced in [ Read More ]
Nurse Navigators Promote Patient Adherence to Treatment Plan
Oral therapies for treating cancer are being developed at an unprecedented rate. Oncology providers, nurses, and pharmacists are now challenged with effectively helping patients manage their cancer treatments in the [ Read More ]
Changing Patient Perceptions to Promote Adherence to Oral Antimyeloma Oncolytics
The management of multiple myeloma (MM) is undergoing a seismic shift from acute treatment to a chronic care model that requires long-term treatment. This trend is fueled by the availability [ Read More ]
Managing Patient Perceptions of Oral Anticancer Therapies
For many years, patients with multiple myeloma have been visiting an infusion facility to receive their cancer treatments. Although patients love their oncology team, trips to the infusion facility can [ Read More ]
The Pivotal Role of Oncology Nurses in the Care of Patients with Multiple Myeloma
The past decade has witnessed dramatic progress in the treatment of multiple myeloma (MM), which has resulted in unprecedented improvements in survival outcomes. According to the Surveillance, Epidemiology, and End [ Read More ]
Conquering the Multiple Myeloma Continuum, Multiple Myeloma
Incorporating Oral Therapy Compliance into the Routine of Patients with Myeloma
Oral oncolytics represent 25% to 35% of the drugs in the oncology pipeline.1 They are patient friendly, allow patients to manage their treatment, and overall, have a less disruptive effect [ Read More ]
Conquering the Multiple Myeloma Continuum, Multiple Myeloma
A New Era of Oral Therapies for Multiple Myeloma : Implementing routines and strategies to promote adherence
Recent advancements in the treatment of multiple myeloma (MM) have led to significant improvements in patient outcomes, including unprecedented survival rates.1 Such progress has allowed a paradigm shift toward a [ Read More ]
Conquering the Multiple Myeloma Continuum, Multiple Myeloma
How to Communicate with Patients with Myeloma to Achieve the Best Outcomes
Treating cancer with oral medications that are taken at home sounds like a great idea, and it is, once adherence barriers are addressed. Likewise, years ago it was unthinkable that [ Read More ]
Conquering the Multiple Myeloma Continuum, Multiple Myeloma
Navigators Are Key in Encouraging Oral Therapy Adherence
Welcome to our first newsletter in the Conquering the Multiple Myeloma Continuum series, which focuses on adherence to oral medications in patients with multiple myeloma (MM). In this first newsletter, [ Read More ]
Conquering the Multiple Myeloma Continuum, Multiple Myeloma
Navigators Are Key in Encouraging Oral Therapy Adherence
Welcome to our first newsletter in the Conquering the Multiple Myeloma Continuum series, which focuses on adherence to oral medications in patients with multiple myeloma (MM). In the first newsletter, [ Read More ]
Conquering the Multiple Myeloma Continuum, Multiple Myeloma
A New Era of Oral Therapies for Multiple Myeloma : Implementing routines and strategies to promote adherence
Recent advancements in the treatment of multiple myeloma (MM) have led to significant improvements in patient outcomes, including unprecedented survival rates.1 Such progress has allowed a paradigm shift toward a [ Read More ]
Incorporating Oral Therapy Compliance into the Routine of Patients with Myeloma
Oral oncolytics represent 25% to 35% of the drugs in the oncology pipeline.1 They are patient friendly, allow patients to manage their treatment, and overall, have a less disruptive effect [ Read More ]
How to Communicate with Patients with Myeloma to Achieve the Best Outcomes
Treating cancer with oral medications that are taken at home sounds like a great idea, and it is, once adherence barriers are addressed. Likewise, years ago it was unthinkable that [ Read More ]
Establishing and Managing Expectations for Length of Therapy in Multiple Myeloma
Multiple Myeloma Nurse Roundtable Saturday, October 5, 2013 Boston, Massachusetts The roundtable was supported by Takeda, and was comprised of oncology nurses, advanced practitioners, and oncology nurse navigators. The purpose [ Read More ]
